Skip to main content
. Author manuscript; available in PMC: 2019 Jan 22.
Published in final edited form as: J Invest Dermatol. 2017 Jun 7;137(10):2187–2196. doi: 10.1016/j.jid.2016.12.033

Figure 4. p90RSK inhibition reduces proliferation in dual resistant melanoma through a mixture of apoptosis induction and growth arrest.

Figure 4.

(a, b) Propidium iodide+BrdU cell cycle flow cytometry showed a significantly greater fold reduction in cells in the S phase after a 30-minute pulse followed by a 2-hour chase with 5 μM BI-D1870 triple therapy over dual 5 μM Vem + 150 nM Sel alone. *P < 0.05, **P < 0.01, mean ± SEM, N = 3. (c) Dual annexin V and propidium iodide flow cytometry showed a significantly larger increase in apoptosis induction by 5 μM BI-D1870 in 72-hour triple therapy over dual Vem + Sel alone. *P < 0.05, **P < 0.01, mean ± SEM, N = 3. APC, antigen-presenting cell; p90RSK, p90 subfamily of ribosomal S6 kinase; SEM, standard error of the mean.